Skip to content

Search

Pioneering paediatric oncologist receives top cancer research award

Associate Professor Rishi Kotecha, Co-Head of Leukaemia Translational Research at The Kids Research Institute Australia Cancer Centre and Consultant Paediatric Oncologist at Perth Children's Hospital, has been named Cancer Council WA’s 2024 Cancer Researcher of the Year.

Invasive fungal disease and antifungal prophylaxis in children with acute leukaemia: a multicentre retrospective Australian cohort study

Invasive fungal disease (IFD) is a common and important complication in children with acute myeloid leukaemia (AML). We describe the epidemiology of IFD in a large multicentre cohort of children with AML.

Invasive pneumococcal disease in children with acute lymphoblastic leukaemia

To determine the incidence, serotype distribution and clinical outcomes of invasive pneumococcal disease in children with acute lymphoblastic leukaemia following widespread use of pneumococcal conjugate vaccines.

New study uncovers dual benefit of bone-protecting treatment for childhood leukaemia

A groundbreaking study from cancer researchers at The Kids Research Institute Australia has identified a promising new therapeutic strategy for children battling the most common childhood cancer – B-cell acute lymphoblastic leukaemia.

Grants power next wave of childhood cancer research

Eight childhood cancer researchers have been awarded over $2 million in transformative grants from Cancer Council WA to advance their pioneering work in improving cancer treatments and outcomes for patients in Western Australia and around the world.

Treatment and Survival Outcomes for Indigenous and Non-Indigenous Australians Within the Victorian Lung Cancer Registry: A Retrospective Cross-Sectional Cohort Study

Our goal was to explore and compare risk factors, patterns of management and survival outcomes in Indigenous compared with non-Indigenous Australian patients using the Victorian Lung Cancer Registry.

A Systematic Review on the Role of Postoperative Radiotherapy in Pelvic Ewing Sarcoma

Ewing Sarcoma of the pelvis has poorer outcomes than other anatomical sites, with complex anatomy often precluding resection with wide margins. The role of postoperative radiotherapy (RT) in improving outcomes remains undefined. A systematic review using Medline, Embase and Cochrane databases (1972-April 2024) evaluated postoperative RT's impact on local recurrence, event-free survival and overall survival. Twenty-nine retrospective studies (21 to 296 patients) met inclusion criteria, with 28 rated good quality.

Current gaps in knowledge and future research directions for Aboriginal and Torres Strait Islander children with cancer

Paediatric cancer is the leading cause of disease-related death in Australian children. Limited research focuses on cancer in Aboriginal and Torres Strait Islander children. Although there appears to be a lower incidence of cancer overall in Aboriginal and Torres Strait Islander children compared with non-Indigenous children, a high proportion of Aboriginal and Torres Strait Islander children are diagnosed with acute myeloid leukaemia.

Deciphering IGH rearrangement complexity and detection strategies in acute lymphoblastic leukaemia

Acute lymphoblastic leukaemia is a highly heterogeneous malignancy characterised by various genomic alterations that influence disease progression and therapeutic outcomes. Gene fusions involving the immunoglobulin heavy chain gene represent a complex and diverse category.

Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemia

There are few options for patients with relapse/refractory B-cell acute lymphoblastic leukemia, thus this is a major area of unmet medical need. Here, we reveal that inclusion of a poison exon in RBM39, which could be induced both by CDK9 or CDK9 independent CMGC (cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinases, CDC-like kinases) kinase inhibition, is recognized by the nonsense-mediated mRNA decay pathway for degradation.